|

Diagnostic Performance of [18F]PSMA-1007 in the Context of Biochemical Recurrence of Prostate Cancer

RECRUITINGSponsored by Heinrich-Heine University, Duesseldorf
Actively Recruiting
SponsorHeinrich-Heine University, Duesseldorf
Started2024-11-01
Est. completion2026-11-30
Eligibility
Age18 Years+
SexMALE
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06657131

Summary

Following numerous retrospective studies and Phase-3-Studies with promising results, \[18F\]PSMA-1007 has been approved by european authorities. Therefore, it is a growing deployment of this diagnostic method anticipated. This study aims to investigate the diagnostic performance and clinical impact in a real-world-evidence in the context of regular clinical care. The evidence generated by this approach is supposed to assist in optimizing the management of prostate cancer patients.

Eligibility

Age: 18 Years+Sex: MALEHealthy volunteers accepted
Inclusion Criteria:

* Informed Consent
* Conduct of \[18F\]PSMA-1007 PET Imaging in the context of regular clinical care

Exclusion Criteria:

* Technical Flaws in the acquisition protocol

Conditions4

Biochemical Persistence of Prostate CancerBiochemical Recurrence of Malignant Neoplasm of ProstateCancerProstate Cancer After a Radical Treatment

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.